Evidence map›Paper›PMID 42491306›Full record

ArticleInternational journal of pharmaceutics: X2026

A Self-assembly Carrier-Free Nanovaccine based on Fluorinated CpG and Neoantigen Peptides for Hepatocellular Carcinoma Immunotherapy.

Xiuyun Lin, Hui Li, Jie Liu, Guangfeng Wu, Liuqing Yao, Zhouwei Zhan, Xiufang Yang, Xiu Yang, Shuxian Cai, Na Yao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xiuyun LinDepartment of Hepatopancreatobiliary Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, PR China.
Hui LiDepartment of Hepatopancreatobiliary Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, PR China.
Jie LiuDepartment of Hepatopancreatobiliary Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, PR China.
Guangfeng WuDepartment of Hepatopancreatobiliary Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, PR China.
Liuqing YaoDepartment of Hepatopancreatobiliary Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, PR China.
Zhouwei ZhanDepartment of Hepatopancreatobiliary Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, PR China.
Xiufang YangDepartment of Hepatopancreatobiliary Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, PR China.
Xiu YangDepartment of Hepatopancreatobiliary Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, PR China.
Shuxian CaiInnovation Center for Cancer Research, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, PR China.
Na YaoDepartment of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, PR China.
Fengfang ChenCollege of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian 350108, PR China.
Wenqiang YanDepartment of pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, PR China.
Peng LyuCollege of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian 350108, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoantigen peptides evade central thymic tolerance due to their absence in normal tissues, making neoantigen vaccines a leading strategy for personalized cancer immunotherapy. Although nanoparticle-based delivery systems are widely used to enhance neoantigen immunogenicity, traditional nanovaccines often incorporate multiple adjuvants and inert carriers, which could hinder efficient antigen delivery and raise biosafety concerns. Herein, we report a carrier-free neoantigen nanovaccine (CpG-2'F/Neo

Indexed as

Carrier-free nanovaccine；immunotherapyHepatocellular carcinomaNeoantigen nanovaccine

Identifiers

PMID42491306
PMCPMC13377477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.